Key result
Normal-weight NAFLD in CVD is linked to ~23% higher visceral adiposity index.
Why the study?
Although non-alcoholic fatty liver disease is typically associated with overweight and obesity, excess visceral fat also occurs in patients with normal body weight, and its role in hepatic and cardiac changes across body weight categories required evaluation.
Does visceral obesity contribute to hepatic fibrosis and adverse cardiac remodeling in cardiovascular disease patients with non-alcoholic fatty liver disease and normal body weight compared to overweight/obese NAFLD patients and non-NAFLD controls?
Cross-Sectional (n=135)
Open-label
Does visceral obesity contribute to hepatic fibrosis and adverse cardiac remodeling in cardiovascular disease patients with non-alcoholic fatty liver disease and normal body weight compared to overweight/obese NAFLD patients and non-NAFLD controls?
Patients with cardiovascular disease and normal-weight NAFLD exhibit visceral adiposity, liver fibrosis markers, and adverse left ventricular remodeling (elevated LV mass index and diastolic dysfunction) comparable to overweight and obese NAFLD patients.
Answers are grounded in this paper and cite their sources.
May indicate hidden cardiometabolic risk despite normal weight; leaves open whether visceral fat assessment improves risk stratification or outcomes.
Вackground. Non-alcoholic fatty liver disease (NAFLD) occupies a leading place in the world among liver diseases and is accompanied by the development of steatosis and steatohepatitis, and in some cases progressing to cirrhosis and hepatocarcinoma. It is generally believed that NAFLD in most cases is associated with overweight and obesity. However, excess visceral fat is also found in patients with normal body weight (BMI). Aim. The aim of this study was to evaluate the role of visceral obesity (VO) in the formation of hepatic and cardiac changes in patients with NAFLD and normal body weight, overweight and obesity. Materials and methods. The study included 135 patients with cardiovascular diseases (arterial hypertension, ischemic heart disease (IHD)) and NAFLD between the ages of 45 and 65, what formed 3 groups: with normal body weight (NBW) overweight and obesity. The control group – 30 patients without a history of NAFLD, aged 50 to 63 years. All patients underwent an assessment of anthropometric parameters (height, weight, body mass index, measurement of WHR (W: H) = Waist circumference / Hip circumference, echocardiography, biochemical blood tests with determination of liver condition by calculated Fatty Liver Index (FLI) and Fibrosis‑4 index (FIB‑4), calculation of Visceral Adiposity Index (VAI) and Relative Fat Mass (RFM) indexes. Results. It was found that the severity of VO in patients with NAFLD and NBW was comparable with patients who were overweight and obesity in indexes: Waist circumference / Hip circumference (WHR), VAI, presence of signs of severe dysfunction of Visceral adipose tissue (VAT), and the RFM index. In the group of patients with NAFLD and NBW, VAI correlated with the severity of liver fibrosis FIB‑4, and RFM with indicators characterizing liver damage. Conclusion. The data obtained indicate the need to understand the pathogenetic features of the formation of a new NAFLD phenotype in order to develop effective therapy for this category of patients.
No takes yet. Share an insight, caveat, or question.
Туркина et al. (2026) conducted a cross-sectional in Cardiovascular disease (arterial hypertension, ischemic heart disease) and non-alcoholic fatty liver disease (NAFLD) (n=135). Non-alcoholic fatty liver disease (NAFLD) with normal body weight and visceral obesity vs. Overweight/obese NAFLD patients and overweight CVD patients without NAFLD was evaluated on Visceral Adiposity Index (VAI), liver fibrosis (FIB-4), and left ventricular mass index (LVMI) (p=<0.0001). Normal-weight NAFLD patients with CVD had higher visceral adiposity and LV mass index than controls without NAFLD.
Synapse has enriched 10 related papers. Consider them for comparative context: